Published on January 24, 2022

COVID-19 Update: Updated Numbers, COVID-19 Treatment Options

COVID-19 By The Numbers

This graphic illustrates the number of patients in Owensboro Health hospitals as of 8 a.m. today that tested positive for COVID-19. Some patients may come into the hospital for other reasons, like to give birth, and test positive. However, the vast majority of the cases you see represented here (roughly 90%) are being treated specifically for COVID-19. It’s important to note that anyone who is COVID-19 positive requires a special level of care and extra precautions.

Hospitalized COVID Patients

Numbers from the infographic are listed as live text below. (Updated as of January 24, 2022)

Totals of all Owensboro Health Hospitals:

  • Critical Care: 15
  • Intubated: 5
  • Total Hospitalized: 66
  • Peak: 85

Owensboro Health Regional Hospital

  • Critical Care: 10 unvaccinated
  • Intubated: 5 unvaccinated
  • Total Hospitalized: 36 unvaccinated, 15 vaccinated 
  • Peak: 69

Owensboro Health Muhlenberg Community Hospital 

  • Critical Care: 2 unvaccinated
  • Intubated: None
  • Total Hospitalized: 4 unvaccinated, 2 vaccinated
  • Peak: 8

Owensboro Health Twin Lakes Medical Center

  • Critical Care: 2 unvaccinated, 1 vaccinated
  • Intubated: None
  • Total: 5 unvaccinated, 4 vaccinated
  • Peak: 21 

COVID-19 Patients by Age

  • Under 20: None
  • 20-29: 1 intubated in critical care, 5 hospitalized
  • 30-39: 2 hospitalized
  • 40-49: 3 in critical care
  • 50-59: 1 intubated in critical care, 3 in critical care, 6 hospitalized
  • 60-69: 2 intubated in critical care, 1 in critical care, 10 hospitalized
  • 70-79: 2 intubated in critical care, 1 in critical care 15 hospitalized
  • 80-89: 1 in critical care, 13 hospitalized
  • 90+: None

 COVID-19 Treatment Options

Monoclonal Antibodies

Monoclonal antibodies for treating COVID-19 continue to be in short supply across the nation. In the last seven days, there were over 72,000 new cases in Kentucky. The state was only allocated 546 doses of Sotrovimab. Last week Owensboro Health received 24 doses of Sotrovimab, the only infusion currently approved for treating the omicron variant of COVID-19. Supplies are not expected to improve the next few weeks.

Oral Therapies

Paxlovid is an oral therapy authorized for emergency use by FDA under an EUA, for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. Paxlovid is not authorized for use as a pre-exposure or post-exposure prophylaxis for prevention for COVID-19.
Paxlovid should be initiated as soon as possible after diagnosis of COVID-19, and within 5 days of symptom onset.  Therapy is twice daily dosing for 5 days. Renal adjustments are necessary depending on the level of renal function.
Despite over 72,000 new COVID cases in the last seven days, the state of Kentucky was only allocated 550 treatment courses of Paxlovid last week. Owensboro Health received enough supply to treat 80 patients. The expectation is Owensboro Health will receive a limited allocation this week as well.

Molnuparivir is another oral therapy authorized for emergency use by FDA under an EUA, for the treatment of mild-to-moderate COVID-19.  This therapy comes with several monitoring challenges such as the need for negative pregnancy tests in females and males to use contraception for 3 months after treatment. The state has contracted with Walgreens pharmacy to dispense this medication across Kentucky.  There are no plans at this time for Owensboro Health to obtain this therapy.

Prophylactic Therapy

Evusheld is a long acting monoclonal antibody used prophylactically for patients at most risk of death or hospitalization. Evusheld is authorized for patients not currently infected with COVID-19 and who have not been recently exposed.  Evusheld is also to be reserved for vaccinated patients who are severely immunocompromised and cannot mount an appropriate response to COVID-19 or who meets this criteria, but cannot be vaccinated due to a history of severe reactions to the vaccine components.  This is NOT to be treated as an alternative to vaccination. Currently Owensboro Health has over 85 doses of Evusheld in stock.

Access to COVID-19 Treatment Options

Owensboro Health and non-Owensboro Health providers can access this site by the following three options:

1.   Open the following hyperlink:  https://www.owensborohealth.org/covid-19-therapies

2.   Visit the Owensboro Health website and select “Covid-19 Therapies”.

https://lh3.googleusercontent.com/a-yeDykcPMr5xGk268JzbvcuCrtoCSilVnKFK8HhbUJhoVPOcY1IZz26DNwcohoZYr7EaneyD_SQwNYH9cEIM-gAmxDLdMr_w-Z1goZiuO8p5x5NqWWddAz5yWha7zE0ea061Iog

3.   They can also google “Owensboro Health COVID Treatment.”

In order to be treated for COVID-19 by antibody infusion or other therapies, patients must see a doctor and be referred to the hospital for treatment.

About Owensboro Health

Owensboro Health is a nonprofit health system with a mission to heal the sick and to improve the health of the communities it serves in Kentucky and Indiana. The system includes Owensboro Health Regional Hospital, nationally recognized for design, architecture and engineering; Owensboro Health Muhlenberg Community Hospital; Owensboro Health Twin Lakes Medical Center; the Owensboro Health Medical Group comprised of over 200 providers at more than 20 locations; three outpatient Healthplex facilities, a certified medical fitness facility, the Healthpark; a surgical weight loss center and program, and the Mitchell Memorial Cancer Center.

On average each year, we have 16,000 inpatient admissions, deliver 2,000 babies and provide the region’s only Level III NICU. Owensboro Health physicians perform nearly 24,000 surgical procedures, including nearly 200 open-heart surgeries. Our physicians and staff have 70,000 Emergency Department visits, more than a million outpatient visits annually. Visit our home page for more information.